Dernière mise à jour :
26/03/2024
Antibiotique   Gentamicin sulfate  
Injectable
Collyre
Stabilité des solutions Stabilité en mélange Facteur influençant la stabilité Compatibilités Voie d’administration Bibliographie Pdf
   Structure chimique  

Noms commerciaux   Noms commerciaux     

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Amplomicina Brésil
Azupel Pérou
Cidomycin Egypte, Grande Bretagne, Irlande
Dabroson Grèce
Epigent Egypte
Garalone Portugal
Garamicina Brésil
Garamycin Afrique du sud, Croatie, Danemark, Egypte, Grèce, Norvège, Slovénie, Suède, Suisse, Turquie
Gencin Allemagne
Genmisin Turquie
Gensif Turquie
Gensumycin Finlande, Norvège, Suède
Genta Turquie
Genta-Gobens Espagne
Gentalline France
Gentamen Italie
Gentamival Espagne
Gentaplus Brésil
Genticin Grande Bretagne
Gentomil Italie
Gentreks Turquie
Geomycine Belgique
Getamisin Turquie
Gevramycin Espagne
Hexamycin Danemark
Plurisemina Argentine
Refobacin Allemagne, Autriche
Regaminol Egypte
Rupegen Argentine
Bibliographie   Injectable   Bibliographie : Gentamicin sulfate  
Type Source
3 Revue Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
19 Revue Bell RG, Lipford LC, Massanari MJ, Riley CM.
Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin.
Am J Hosp Pharm 1986 ; 43: 1444-1453.
57 Revue Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
59 Revue Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63 Revue Marquardt Ed, Lam SSY.
Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 811-812.
73 Revue Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
84 Revue Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Revue Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104 Revue Hall PD, Yui D, Lyons S, Bosso JA.
Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 185-189.
129 Revue Smythe M, Malouf E.
Visual compatibility of insulin with secondary intravenous drugs in admixtures.
Am J Hosp Pharm 1991 ; 48: 125-126.
132 Revue Najari Z, Rusho WJ.
Compatibility of commonly used bone marrow transplant drugs during Y-site delivery.
Am J Health-Syst Pharm 1997 ; 54: 181-184.
169 Revue Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
176 Revue Mantong ML, Marquardt ED.
Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
186 Revue Swart EL, Mooren RAG, Van Loenen AC.
Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198 Revue Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
215 Revue Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M.
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs.
Ann Pharmacotherapy 1993 ; 27: 422-426.
244 Revue Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 Revue Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 Revue Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253 Revue Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528.
256 Revue Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA.
Stability of fluconazole in commonly used intravenous antibiotic solutions.
Am J Hosp Pharm 1993 ; 50: 1206-1208.
266 Revue Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
280 Revue Allen LV, Stiles ML, Prince SJ, Sylvestri MF.
Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 2427-2433.
285 Revue Elmore RL, Contois ME, Kelly J, Noe A, Poirier A.
Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs.
Clin Ther 1996 ; 18: 246-255.
288 Revue Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962.
289 Revue Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707.
299 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Revue Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Revue Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Revue Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
315 Revue Bahal SM, Lee TJ, McGinnes M, Dobler GL.
Visual compatibility of warfarin sodium injection with selected medications and solutions.
Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316 Revue Veltri M, Lee CKK.
Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs.
Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
317 Revue Kershaw BP, Monnier HL, Mason JH.
Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration.
Am J Hosp Pharm 1993 ; 50: 1360-1362.
334 Revue Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 Revue Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
336 Revue Forman JK, Lachs JR, Souney PF.
Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.
Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Revue Bashaw ED, Amantea MA, Minor JR, Galleli JF.
Visual compatibility of zidovudine with other drugs during simulated Y-site administration.
Am J Hosp Pharm 1988 ; 45: 2532-2533.
367 Revue Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119.
384 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 630-632.
385 Revue Benedict MK, Roche VF, Banakar UV, Hilleman DE.
Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1117-1118.
386 Revue Colucci RD, Cobuzzi LE, Halpern NA.
Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1988 ; 45: 1357-1358.
397 Revue Fong PA, Ward J.
Visual compatibility of intravenous famotidine with selected drugs.
Am J Hosp Pharm 1989 ; 46: 125-126.
402 Revue Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
405 Revue Nieves-Cordero AL, Luciw HM, Souney PF.
Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1985 ; 42: 1108-1109.
406 Revue Smythe MA, Patel MA, Gasloli RA.
Visual compatibility of narcotic analgesics with selected intravenous admixtures.
Am J Hosp Pharm 1990 ; 47: 819-820.
423 Revue Mansur JM, Abramowitz PW, Lerner SA, Smith RB, Townsend RJ.
Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours.
Am J Hosp Pharm 1985 ; 42: 332-335.
434 Revue Goodwin SD, Nix DE, Heyd A, Wilton JH.
Compatibility of ciprofloxacin injection with selected drugs and solutions.
Am J Hosp Pharm 1991 ; 48: 2166-2171.
472 Revue Wohlford JG, Fowler MD.
Visual compatibility of hetastarch with injectable critical-care drugs.
Am J Hosp Pharm 1989 ; 46: 995-996.
479 Revue Min DI, Brown T, HWang GC.
Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 2964-2966.
491 Revue Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Revue Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
494 Revue Thompson DF, Heflin NR.
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate.
Am J Hosp Pharm 1992 ; 49: 836,838.
496 Revue Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
565 Revue Marble DA, Bosso JA, Townsend RJ.
Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions.
Drug Intell Clin Pharm 1986 ; 20: 960-963.
573 Revue Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL.
Stability of antibiotic admixtures frozen in minibags.
Drug Intell Clin Pharm 1977 ; 11: 542-548.
576 Revue Holmes CJ, Ausman RK, Walter CW, Kundsin RB.
Activity of antibiotic admixtures subjected to different freeze-thaw treatments.
Drug Intell Clin Pharm 1980 ; 14: 353-357.
604 Laboratoire Stabilité des médicaments dans l'Intermate® SV50, 100, 200
Baxter 1998
612 Revue Frable RA, Klink PR, Engel GL, Mundell EE.
Stability of cefamandole nafate injection with parenteral solutions and additives.
Am J Hosp Pharm 1982 ; 39: 622-627.
639 Revue Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ.
Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes.
Drug Intell Clin Pharm 1987 ; 21: 806-810.
660 Revue Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
673 Revue Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD.
The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures.
JPEN 1989 ; 13: 505-509.
695 Revue Zbrozek AS, Marble DA, Bosso JA.
Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions.
Drug Intell Clin Pharm 1988 ; 22: 873-875.
738 Revue Gardella LA, Kesler H, Amann A, Carter JE.
Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives.
Am J Hosp Pharm 1978 ; 35: 581-584.
789 Revue Garner SS, Wiest DB.
Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system.
Am J Hosp Pharm 1990 ; 47: 604-606.
805 Revue Oskroba DM, Leissing NC, Trissel LA.
An automated process for determining the physical compatibility of drugs.
Hosp Pharm 1997 ; 32: 1013-1020.
889 Revue Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM.
Ofloxacin intravenous. Compatibility with other antibacterial agents.
Pharm Weekbl [Sci] 1991 ; 13: 207-209.
905 Revue Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Revue Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
939 Revue Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
999 Revue Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1022 Revue Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886.
1035 Revue Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132.
1047 Revue Souney PF, Colucci RD, Mariani G, Campbell D.
Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection.
Am J Hosp Pharm 1984 ; 41: 323-324.
1057 Revue Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072 Revue Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA.
Compatibility of levofloxacin with 34 medications during simulated Y-site administration.
Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1085 Revue Irving HD, Burbridge BE.
Incompatibility of contrast agents with intravascular medications.
Radiology 1989 ; 173: 91-92.
1135 Revue Baltz JK, Kennedy P, Minor JR, Gallelli J.
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1990 ; 47: 2075-2077.
1201 Revue Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG.
Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures.
Am J Hosp Pharm 1981 ; 38: 1919-1922.
1206 Revue Frear RS.
Cefoperazone-aminoglycoside incompatibility.
Am J Hosp Pharm 1983 ; 40: 564.
1232 Revue Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1243 Revue Rovers JP, Meneilly G, Souny PF, Rekhi GS, Drum D.
The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole / gentamicin admixtures.
Can J Hosp Pharm 1989 ; 42: 143-146.
1258 Revue Tyler LS, Rehder TL, Davis RB.
Effect of gentamicin on heparin activity.
Am J Hosp Pharm 1981 ; 38: 537-540.
1315 Revue Halpern NA, Colucci RD, Alicea M, Greenstein R.
Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1322 Revue Ennis CE, Merritt RJ, Neff DN.
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients.
JPEN 1983 ; 7: 156-158.
1410 Revue Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Revue Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Revue Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1486 Revue Nahata MC, Hipple TF, Strausbaugh SD.
Stability of gentamicin diluted in 0.9% sodium chloride injection in glass syringes.
Hosp Pharm 1987 ; 22: 1131-1132.
1490 Revue Halpern NA, Colucci RD, Alicea M, Greenstein R.
The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1625 Revue Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1704 Revue Xu QA, Trissel LA, Saenz A.
Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags.
Int J Pharm Compound 2002 ; 6: 152-154.
1712 Revue Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Revue Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Revue Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1745 Revue Thompson DF, Heflin NR.
Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate.
Am J Health-Syst Pharm 1992 ; 49: 836-838.
1754 Revue Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1759 Revue Servais H, Tulkens PM.
Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients.
Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1800 Revue Voytilla KL, Tyler LS, Rusho WJ.
Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.
Am J Health-Syst Pharm 2002 ; 59: 853-855.
1802 Revue Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803 Revue Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1888 Revue Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A.
Compatibility study of midazolam.
Ziekenhuisfarmacie 1986 ; 2: 45-48.
1917 Revue Graham AE, Speicher E, Williamson B.
Analysis of gentamicin sulfate and a study of its degradation in dextrose solution.
J Pharm Biomed Anal 1997 ; 15: 537- 543.
1925 Revue Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1937 Revue Lai JJ, Brodeur SK.
Physical and chemical stability of daptomycin with nine medications.
Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953 Revue Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982 Revue Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017 Revue Barker B, Feddema S, Rusho WJ, Dengg R.
Visual compatibility of vasopressin with other injectable drugs.
Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2019 Revue Wazny L, Walker S, Moist L.
Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions.
Am J Health-Syst Pharm 2005 ; 62: 1548-1550.
2087 Revue Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Revue Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2109 Revue Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75.
2141 Revue Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM.
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
J Antimicrob Chemother 2003 ; 51: 651-658.
2228 Revue Kupiec T, Ben M, Trusley C, Trissel LA.
Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration.
Int J Pharm Compound 2008 ; 12,2: 170-173.
2231 Revue de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S.
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247 Revue Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Revue Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Revue Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2271 Laboratoire Daptomycine (Cubicin®) Résumé des caractéristiques du produits
Novartis 2006
2296 Laboratoire Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
2335 Revue Canann D, Tyler L.S, Barker B, Condie C.
Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients
Am J Health-Syst Pharm 2009 ; 66, 8: 727-729
2353 Revue Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y.
Compatibility and stability of linezolid injection admixted with gentamicin sulfate and tobramycin sulfate.
Int J Pharm Compound 2000 ; 4, 6: 476-479.
3012 Revue Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3122 Revue Dotson B, Lynn S, Savakis K, Churchwell MD.
Physical compatibility of 4% sodium citrate with selected antimicrobial agents.
Am J Health-Syst Pharm 2010 ; 67: 1195-1198.
3128 Laboratoire Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013
3141 Revue Cote D, Lok CE, Battistella M, Vercaigne L.
Stability of Trisodium Citrate and Gentamicin Solution for Catheter Locks after Storage in Plastic Syringes at Room Temperature.
Can J Hosp Pharm 2010 ; 63, 4: 304-311.
3152 Revue Kumar A, Mann HJ.
Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3201 Revue Dice JE.
Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit.
J Pediatr Pharmacol Ther 2006 ; 11:233?6.
3216 Revue Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Revue Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Revue Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332 Laboratoire Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3372 Revue Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S.
Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine.
Rev Bras Anestesiol 2013 ; 63, 1: 163-166.
3385 Revue Raverdi V, Ampe E, Hecq JD, Tulkens PM.
Stability and compatibility of vancomycin for administration by continuous infusion.
J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408 Revue Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3520 Laboratoire Cidomycin - Summary of product Chracteristics.
Sanofi 2011
3522 Laboratoire Flucloxacillin - Summary of Product Characteristics.
Actavis 2013
3523 Laboratoire Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Laboratoire Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3527 Laboratoire Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018
3540 Laboratoire Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3543 Laboratoire Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3544 Laboratoire Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006
3545 Laboratoire Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3546 Laboratoire Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3548 Laboratoire Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3578 Laboratoire Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3580 Laboratoire Cytarabine Accord - Résumé des caractéristiques du produit
Accord Healthcare France 2016
3586 Laboratoire Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010
3587 Laboratoire Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014
3594 Laboratoire Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013
3638 Laboratoire Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics
Hospira 2010
3643 Laboratoire Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics
Sanofi 2015
3644 Laboratoire Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3656 Laboratoire Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014
3674 Laboratoire Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3677 Laboratoire Cefpirome (Cefrom®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2008
3687 Laboratoire Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3766 Revue Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Revue Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3824 Revue Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3883 Laboratoire Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016
3888 Revue Ranganathan D, Naicker S,. Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A
Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).
Perit Dial Int 2016 ; 36:421-426.
3952 Revue Battistella M,. Vercaigne L.M, Cote D,. Lok C.E.
Antibiotic lock: In vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37°C.
Hemodial Int 2010 ; 14, 3 : 322-326.
3956 Revue Bastani B; Amin K; Herr A.
Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique.
ASAIO Journal 2005 ; 51,6:761-763.
3964 Revue Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4055 Revue Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4254 Revue D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319 Revue Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4354 Poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables.
GERPAC Congress 2019 2019
4380 Laboratoire Posaconazole (Noxafil®) - Summary of Product Characteristics
Merck Sharp & Dohme Limited 2019
4434 Revue Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4440 Revue Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.
Ann Nutr Metab 2018 ; 73: 227-233.
4445 Revue Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D.
Antibiotic compatibility and stability in a parenteral nutrition solution.
Chemotherapy 1979 ; 25: 336-345.
4471 Laboratoire Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019
4507 Revue Ross E, Salinas A, Petty K, Her C, Carpenter J.
Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing.
Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4524 Poster Stucki C, Sautter A-M, Bonnabry P.
Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology.
ESCP Symposium, Geneva, Switzerland 2009
4528 Revue Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4543 Revue Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603 Revue Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4612 Revue Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E.
Estabilidad de la solución de gentamicina y heparina para sellado de catéter.
OFIL 2014 24;2:86-90
4642 Poster Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner
Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia.
SEFH Congress (Virtual) October 2021 2021
4650 Laboratoire Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4654 Poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021
4742 Revue Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales